메뉴 건너뛰기




Volumn 100, Issue 11, 2011, Pages 955-971

Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011

Author keywords

ARISTOTLE; ASCOT; CORP; CRISP AMI; dal VESSEL; ECOST; EMPHASIS HF; EVATEL; EXAMINATION; HCS; IRIS; KYOTO HEART Study; ONTARGET; PACE; PRODIGY; PURE; RE LY; RESET; ROCKET AF; RUBY 1 trial; SHIFT; SMART AV; STICH

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CANDESARTAN; CLOPIDOGREL; COLCHICINE; DABIGATRAN; DALCETRAPIB; DAREXABAN; EPLERENONE; EVEROLIMUS; FONDAPARINUX; HEPARIN; HIRULOG; IVABRADINE; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; PLACEBO; RAMIPRIL; RAPAMYCIN; RIVAROXABAN; STEROID; TELMISARTAN; TORCETRAPIB; UNINDEXED DRUG; VALSARTAN; WARFARIN;

EID: 81255149230     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-011-0370-8     Document Type: Conference Paper
Times cited : (2)

References (39)
  • 1
    • 78649639988 scopus 로고    scopus 로고
    • Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010
    • M Lenski F Mahfoud C Werner A Bauer M Böhm 2010 Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010 Clin Res Cardiol Off J Ger Card Soc 99 679 692
    • (2010) Clin Res Cardiol off J Ger Card Soc , vol.99 , pp. 679-692
    • Lenski, M.1    Mahfoud, F.2    Werner, C.3    Bauer, A.4    Böhm, M.5
  • 4
    • 34447520136 scopus 로고    scopus 로고
    • Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
    • DOI 10.1001/jama.298.3.309
    • S Bansal JE Buring N Rifai S Mora FM Sacks PM Ridker 2007 Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 309 316 17635891 10.1001/jama.298.3.309 1:CAS:528: DC%2BD2sXotValtb0%3D (Pubitemid 47080485)
    • (2007) Journal of the American Medical Association , vol.298 , Issue.3 , pp. 309-316
    • Bansal, S.1    Buring, J.E.2    Rifai, N.3    Mora, S.4    Sacks, F.M.5    Ridker, P.M.6
  • 5
    • 0018649439 scopus 로고
    • Atherogenesis: A postprandial phenomenon
    • DB Zilversmit 1979 Atherogenesis: a postprandial phenomenon Circulation 60 473 485 222498 1:CAS:528:DyaE1MXlsFGntLc%3D (Pubitemid 9254048)
    • (1979) Circulation , vol.60 , Issue.3 , pp. 473-485
    • Zilversmit, D.B.1
  • 6
    • 80052836882 scopus 로고    scopus 로고
    • A new era for anticoagulation in atrial fibrillation
    • doi: 10.1056/NEJMe1109748
    • Mega JL (2011) A new era for anticoagulation in atrial fibrillation. N Engl J Med. doi: 10.1056/NEJMe1109748
    • (2011) N Engl J Med.
    • Mega, J.L.1
  • 13
    • 73849084830 scopus 로고    scopus 로고
    • Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study
    • KYOTO HEART Study Group. 19723695 10.1093/eurheartj/ehp363 1:CAS:528:DC%2BD1MXht12ht7vL
    • T Sawada H Yamada B Dahlöf H Matsubara KYOTO HEART Study Group 2009 Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study Eur Heart J 30 2461 2469 19723695 10.1093/eurheartj/ehp363 1:CAS:528:DC%2BD1MXht12ht7vL
    • (2009) Eur Heart J , vol.30 , pp. 2461-2469
    • Sawada, T.1    Yamada, H.2    Dahlöf, B.3    Matsubara, H.4
  • 14
    • 0006456524 scopus 로고    scopus 로고
    • NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation
    • NK Foundation 1997 NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation Am J kidney Dis Off J Natl Kidney Found 30 3 Suppl 2 S15 S66
    • (1997) Am J Kidney Dis off J Natl Kidney Found , vol.30 , Issue.3 SUPPL. 2
    • Foundation, N.K.1
  • 15
    • 74549183897 scopus 로고    scopus 로고
    • Angiotensin receptor blockers: Baseline therapy in hypertension?
    • 19723696 10.1093/eurheartj/ehp364
    • FH Messerli S Bangalore F Ruschitzka 2009 Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 30 2427 2430 19723696 10.1093/eurheartj/ehp364
    • (2009) Eur Heart J , vol.30 , pp. 2427-2430
    • Messerli, F.H.1    Bangalore, S.2    Ruschitzka, F.3
  • 16
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
    • DOI 10.1016/S0140-6736(03)12948-0
    • PS Sever, et al. 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 9364 1149 1158 12686036 10.1016/S0140-6736(03)12948-0 1:CAS:528:DC%2BD3sXis1yqu7o%3D (Pubitemid 36398384)
    • (2003) Lancet , vol.361 , Issue.9364 , pp. 1149-1158
    • Sever, P.S.1    Dahlof, B.2    Poulter, N.R.3    Wedel, H.4    Beevers, G.5    Caulfield, M.6    Collins, R.7    Kjeldsen, S.E.8    Kristinsson, A.9    McInnes, G.T.10    Mehlsen, J.11    Nieminen, M.12    O'Brien, E.13    Ostergren, J.14
  • 17
    • 80054741504 scopus 로고    scopus 로고
    • The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK
    • doi: 10.1093/eurheartj/ehr333
    • Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, on behalf of the ASCOT Investigators (2011) The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. doi: 10.1093/eurheartj/ehr333
    • (2011) Eur Heart J.
    • Sever, P.S.1    Chang, C.L.2    Gupta, A.K.3    Whitehouse, A.4    Poulter, N.R.5
  • 18
    • 35248901000 scopus 로고    scopus 로고
    • Long-term follow-up of the West of Scotland coronary prevention study
    • DOI 10.1056/NEJMoa065994
    • I Ford H Murray CJ Packard J Shepherd PW Macfarlane SM Cobbe West of Scotland Coronary Prevention Study Group 2007 Long-term follow-up of the West of Scotland Coronary Prevention Study N Engl J Med 35 1477 1486 10.1056/NEJMoa065994 (Pubitemid 47572633)
    • (2007) New England Journal of Medicine , vol.357 , Issue.15 , pp. 1477-1486
    • Ford, I.1    Murray, H.2    Packard, C.J.3    Shepherd, J.4    Macfarlane, P.W.5    Cobbe, S.M.6
  • 21
    • 78650399880 scopus 로고    scopus 로고
    • Eplerenone in patients with systolic heart failure and mild symptoms
    • EMPHASIS-HF Study Group. 21073363 10.1056/NEJMoa1009492 1:CAS:528:DC%2BC3MXisValuw%3D%3D
    • F Zannad JJ McMurray H Krum DJ van Veldhuisen K Swedberg H Shi J Vincent SJ Pocock B Pitt EMPHASIS-HF Study Group 2011 Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11 21 21073363 10.1056/NEJMoa1009492 1:CAS:528:DC%2BC3MXisValuw%3D%3D
    • (2011) N Engl J Med , vol.364 , pp. 11-21
    • Zannad, F.1    McMurray, J.J.2    Krum, H.3    Van Veldhuisen, D.J.4    Swedberg, K.5    Shi, H.6    Vincent, J.7    Pocock, S.J.8    Pitt, B.9
  • 23
    • 16844364826 scopus 로고    scopus 로고
    • The effect of cardiac resynchronization on morbidity and mortality in heart failure
    • DOI 10.1056/NEJMoa050496
    • JG Cleland JC Daubert E Erdmann N Freemantle D Gras L Kappenberger Tavazzi Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators 2005 The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 1539 1549 15753115 10.1056/NEJMoa050496 1:CAS:528:DC%2BD2MXjtFGnsLo%3D (Pubitemid 40517094)
    • (2005) New England Journal of Medicine , vol.352 , Issue.15 , pp. 1539-1549
    • Cleland, J.G.F.1    Daubert, J.-C.2    Erdmann, E.3    Freemantle, N.4    Gras, D.5    Kappenberger, L.6    Tavazzi, L.7
  • 24
    • 56349114416 scopus 로고    scopus 로고
    • Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heartfailure symptoms
    • REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. 19038680 10.1016/j.jacc.2008.08.027
    • C Linde WT Abraham MR Gold M St John Sutton S Ghio C Daubert REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group 2008 Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heartfailure symptoms J Am Coll Cardiol 52 1834 1843 19038680 10.1016/j.jacc.2008.08.027
    • (2008) J Am Coll Cardiol , vol.52 , pp. 1834-1843
    • Linde, C.1    Abraham, W.T.2    Gold, M.R.3    St John Sutton, M.4    Ghio, S.5    Daubert, C.6
  • 28
    • 80054070561 scopus 로고    scopus 로고
    • Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study
    • doi: 10.1093/eurheartj/ehr343
    • Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. doi: 10.1093/eurheartj/ehr343
    • (2011) Eur Heart J.
    • Ekman I, C.1
  • 30
    • 0037179656 scopus 로고    scopus 로고
    • Warfarin, aspirin, or both after myocardial infarction
    • 12324552 10.1056/NEJMoa020496 1:CAS:528:DC%2BD38Xnt12rtLY%3D
    • M Hurlen M Abdelnoor P Smith J Erikssen H Arnesen 2002 Warfarin, aspirin, or both after myocardial infarction N Engl J Med 347 969 974 12324552 10.1056/NEJMoa020496 1:CAS:528:DC%2BD38Xnt12rtLY%3D
    • (2002) N Engl J Med , vol.347 , pp. 969-974
    • Hurlen, M.1    Abdelnoor, M.2    Smith, P.3    Erikssen, J.4    Arnesen, H.5
  • 31
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • DOI 10.1056/NEJMoa010746
    • S Yusuf F Zhao SR Mehta S Chrolavicius G Tognoni KK Fox Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 494 502 11519503 10.1056/NEJMoa010746 1:CAS:528:DC%2BD3MXms1arsrY%3D (Pubitemid 32758501)
    • (2001) New England Journal of Medicine , vol.345 , Issue.7 , pp. 494-502
    • Yusuf, S.1    Zhao, F.2    Mehta, S.R.3    Chrolavicius, S.4    Tognoni, G.5    Fox, K.K.6
  • 32
    • 71749087343 scopus 로고    scopus 로고
    • Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data
    • 20006130 10.1016/S0140-6736(09)61751-7
    • R Sørensen ML Hansen SZ Abildstrom A Hvelplund C Andersson C Jørgensen JK Madsen PR Hansen L Køber C Torp-Pedersen GH Gislason 2009 Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 1967 1974 20006130 10.1016/S0140-6736(09)61751-7
    • (2009) Lancet , vol.374 , pp. 1967-1974
    • Sørensen, R.1    Hansen, M.L.2    Abildstrom, S.Z.3    Hvelplund, A.4    Andersson, C.5    Jørgensen, C.6    Madsen, J.K.7    Hansen, P.R.8    Køber, L.9    Torp-Pedersen, C.10    Gislason, G.H.11
  • 33
    • 80051834654 scopus 로고    scopus 로고
    • Novel oral anticoagulants: Focus on stroke prevention and treatment of venous thromboembolism
    • doi: 10.1093/eurheartj/ehr052
    • Steffel J, Braunwald E (2011) Novel oral anticoagulants: focus on stroke prevention and treatment of venous thromboembolism. Eur Heart J. doi: 10.1093/eurheartj/ehr052
    • (2011) Eur Heart J.
    • Steffel, J.1    Braunwald, E.2
  • 34
    • 80054733922 scopus 로고    scopus 로고
    • RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
    • doi: 10.1093/eurheartj/ehr334
    • Steg PG, Mehta S, Jukema JV, Lip GYH, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. doi: 10.1093/eurheartj/ehr334
    • (2011) Eur Heart J.
    • Steg, P.G.1    Mehta, S.2    Jukema, J.V.3    Gyh, L.4    Gibson, C.M.5    Kovar, F.6    Kala, P.7    Garcia-Hernandez, A.8    Renfurm, R.W.9    Granger, C.B.10
  • 37
    • 67649562905 scopus 로고    scopus 로고
    • Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial
    • ATLAS ACS-TIMI 46 study group. 19539361 10.1016/S0140-6736(09)60738-8 1:CAS:528:DC%2BD1MXotFCgtLc%3D
    • JL Mega E Braunwald S Mohanavelu P Burton R Poulter F Misselwitz V Hricak ES Barnathan P Bordes A Witkowski V Markov L Oppenheimer CM Gibson ATLAS ACS-TIMI 46 study group 2009 Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 29 38 19539361 10.1016/S0140-6736(09)60738-8 1:CAS:528:DC%2BD1MXotFCgtLc%3D
    • (2009) Lancet , vol.374 , pp. 29-38
    • Mega, J.L.1    Braunwald, E.2    Mohanavelu, S.3    Burton, P.4    Poulter, R.5    Misselwitz, F.6    Hricak, V.7    Barnathan, E.S.8    Bordes, P.9    Witkowski, A.10    Markov, V.11    Oppenheimer, L.12    Gibson, C.M.13
  • 38
    • 79955887785 scopus 로고    scopus 로고
    • Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome
    • 21570509 10.1016/j.ahj.2011.01.026 1:CAS:528:DC%2BC3MXmtFansLY%3D
    • CM Gibson JL Mega P Burton S Goto F Verheugt C Bode A Plotnikov X Sun N Cook-Bruns E Braunwald 2011 Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 161 815 821 21570509 10.1016/j.ahj.2011.01.026 1:CAS:528: DC%2BC3MXmtFansLY%3D
    • (2011) Am Heart J , vol.161 , pp. 815-821
    • Gibson, C.M.1    Mega, J.L.2    Burton, P.3    Goto, S.4    Verheugt, F.5    Bode, C.6    Plotnikov, A.7    Sun, X.8    Cook-Bruns, N.9    Braunwald, E.10
  • 39
    • 77955966357 scopus 로고    scopus 로고
    • Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: A randomized controlled trial
    • BCIS-1 Investigators. 20736470 10.1001/jama.2010.1190 1:CAS:528:DC%2BC3cXhtVOksr%2FK
    • D Perera R Stables M Thomas J Booth M Pitt D Blackman A de Belder S Redwood BCIS-1 Investigators 2010 Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial JAMA 304 867 874 20736470 10.1001/jama.2010.1190 1:CAS:528: DC%2BC3cXhtVOksr%2FK
    • (2010) JAMA , vol.304 , pp. 867-874
    • Perera, D.1    Stables, R.2    Thomas, M.3    Booth, J.4    Pitt, M.5    Blackman, D.6    De Belder, A.7    Redwood, S.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.